Payer Perceptions of the Inflation Reduction Act
Lumanity convened medical and pharmacy directors from six large national and regional US payers with at least 25% Medicare business to share their perspectives on both the Maximum Fair Price (MFP) drug price negotiation and Part D redesign components of the IRA. Read the six key insights from our panel.
View Aug 28, 2023
Is Patient Engagement in Regulatory Decisions at a Tipping Point?
To meet the challenge of meeting the growing expectation from regulators for robust patient experience data that demonstrate the impact new products may have for patients and their quality of life, our industry needs to work closely with the patient community, regulators, and other stakeholders.
View Mar 22, 2023